Metabolic Syndrome (MetS) is a complex, multifactorial condition characterized by a cluster of metabolic abnormalities, including obesity, insulin resistance, dyslipidemia, hypertension, and chronic inflammation. It significantly increases the risk of developing type 2 diabetes, cardiovascular diseases, and other metabolic disorders. Recent advances in research highlight the critical role of the gut microbiome as a metabolic organ influencing host metabolism, immune function, and disease progression. This chapter explores the intricate relationship between the gut microbiome and metabolic biomarkers, emphasizing their role in the pathophysiology, diagnosis, and management of MetS. The chapter provides a comprehensive overview of biotic and abiotic factors contributing to MetS, including dietary habits, genetic predisposition, environmental influences, and lifestyle factors such as smoking, alcohol consumption, sleep patterns, and physical activity. It discusses how gut microbial dysbiosis, characterized by an altered Firmicutes/Bacteroidetes ratio, reduced levels of beneficial bacteria such as Akkermansia muciniphila, and shifts in microbial metabolite production (e.g., short- chain fatty acids, bile acids, and trimethylamine-N-oxide), is linked to metabolic dysfunction. Furthermore, this chapter delves into classical metabolic biomarkers (e.g., fasting glucose, lipid profiles, inflammatory markers) and emerging microbiome-derived biomarkers, highlighting their potential in early disease detection and precision medicine. Special attention is given to the gut-brain axis, microbial metabolites, and their impact on insulin sensitivity, immune modulation, and gut barrier integrity. This chapter concludes by discussing emerging therapeutic strategies, including microbiome-targeted interventions such as probiotics, prebiotics, fecal microbiota transplantation, and precision nutrition. Future research directions emphasize the integration of multi-omics approaches, artificial intelligence, and personalized medicine to develop innovative microbiome-based diagnostic and therapeutic solutions for MetS. Understanding the gut microbiome’s role in metabolic health paves the way for novel interventions to mitigate the global burden of metabolic disorders.